T cell development can be mechanically steered in vitro with engineered tissue-mimicking biomaterials, opening new ways to advance cell manufacturing in adoptive T cell therapies
An immune-infiltrated human kidney organoid-on-chip model enables assessment of kidney toxicities to immunotherapeutic T cell bispecific antibody drugs with high resolution
Integrated biomaterials approach that enhances adoptively transferred T cell therapy with cancer vaccine technology provides strong and long-lasting effects against solid tumors
Controlling inflammation enables injured aged muscle recovery via non-invasive mechanical loading, offering promise for the future of mechanotherapies for elderly patients.
Fine-tuning stimulation doses to deficiencies in patient-specific CAR-T cells, using artificial antigen-presenting scaffolds, enables manufacturing of more potent CAR-T cell products.
New tissue engineering capabilities enable researchers to program contractility in functional layers of heart tissue bioprinted with human stem cell-derived organ building blocks
